Introduction: The effect of L-arginine on bladder tissue structure and function in a rat bladder injury model were investigated. Methods: 24 male Sprague-Dawley rats were used. The control group received a regular diet. The L-arginine group received oral L-arginine (1 g/day). The protamine sulfate (PS) group received intravesical PS every 48 h (0.5 ml, 5 mg/ml). L-Arginine was administered to the PS+L-arginine group in addition to PS. At the end of 1 week, bladder tissues were processed for histological and functional studies. Results: The PS group revealed urothelial damage with glycosaminoglycan layer irregularity and mast cell infiltration which was not evident in the PS+L-arginine group. 120 mM potassium and electrical field stimulation (EFS)-induced contractions in the PS group were significantly lower than in other groups, whereas carbachol-induced contractions were not significantly different. Relaxation responses of precontracted strips to EFS and isoproterenol did not reveal a significant decrease in the PS group, whereas L-arginine significantly enhanced these responses in PS-treated animals. Conclusions: Intravesical PS causes urothelial damage and inflammation that is associated with significant changes in rat bladder tissue contractility. Oral L-arginine treatment is found to prevent these histological and contractile alterations. Our findings may indicate the nitric oxide-cGMP pathway as a possible therapeutic target in various bladder diseases associated with urothelial damage.

Keywords:
L-Arginine, Oral L-arginine, prophylactic role, Protamine sulfate, Bladder injury, Rat chronic bladder injury model
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.